Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4E | P06730 | 18/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14797301 | 0.89 | EIF4E (0.74) | EIF4EKDM4EMEN1NPC1RAB9A | |
| SCHEMBL17132708 | 0.85 | EIF4E (0.74) | EIF4EKDM4EMEN1NPC1RAB9A | |
| SCHEMBL14797457 | 0.85 | EIF4E (0.69) | EIF4EKDM4EMEN1NPC1RAB9A | |
| SCHEMBL14797131 | 0.81 | EIF4E (0.71) | EIF4EKDM4EMEN1NPC1RAB9A | |
| SCHEMBL14797279 | 0.80 | EIF4E (0.75) | EIF4E | |
| SCHEMBL14797175 | 0.80 | EIF4E (0.78) | EIF4E | |
| SCHEMBL14797478 | 0.80 | EIF4E (0.74) | EIF4EKDM4EMEN1NPC1RAB9A | |
| SCHEMBL9374807 | 0.77 | THRB (0.65) | EIF4EKDM4EMEN1NPC1RAB9A | |
| SCHEMBL14797454 | 0.76 | EIF4E (0.75) | EIF4E | |
| SCHEMBL14797488 | 0.76 | EIF4E (1.00) | EIF4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409901-B2 | Compositions and methods for treating or preventing diseases or disorders associated with misregulated EIF4E | BANTAM PHARMACEUTICAL, LLC (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150274717-A1 | Compositions And Methods For Treating Or Preventing Diseases Or Disorders Associated With Misregulated EIF4E | EGENIX, INC. | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274717-A1 | Compositions And Methods For Treating Or Preventing Diseases Or Disorders Associated With Misregulated EIF4E | EIF4EBP1, EIF4E, EEF2K | EIF4E 2/4885KDM4E 2325/4885MEN1 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.